Impax Says Pfizer's Detrol Patent Suit Is Baseless

Law360, New York (March 6, 2008, 12:00 AM EST) -- Impax Laboratories Inc. President and Chief Executive Larry Hsu has alleged that Pfizer Inc.'s recent patent suit against Impax over urinary incontinence treatment Detrol LA is a ploy to fend off generic competition in the $857 million annual U.S. market for the drug.

Pfizer hit Impax with an infringement suit on Tuesday, asking the U.S. District Court for the Southern District of New York to find that Impax infringed Pfizer's patents and to block Impax from bringing its proposed generic to market.

“This suit is just...
To view the full article, register now.